Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Capital infusion to accelerate Earendil’s R&D platform
The company plans to submit the vaccine for regulatory review
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
Subscribe To Our Newsletter & Stay Updated
